Literature DB >> 1845482

Immunocytochemical criteria in the differential diagnosis of malignant melanoma versus carcinoma, lymphoma and sarcoma in fine needle aspirates.

W Domagała1, M Chosia, E Bedner, K Weber, M Osborn.   

Abstract

Monoclonal antibodies to keratin, vimentin, leukocyte common antigen (LCA) and S-100 protein have been used in fine needle aspirates of 35 metastatic malignant melanomas, 136 carcinomas, 35 sarcomas and 82 non-Hodgkin's lymphomas in search for immunocytochemical criteria useful in differential diagnosis of melanoma versus carcinoma, non-Hodgkin's lymphoma and sarcoma. All melanomas expressed vimentin and did not express keratin. Six of 14 melanomas contained S-100 protein. All carcinomas were keratin positive. Some were also vimentin positive. All sarcomas expressed vimentin. Synovial sarcomas were also keratin positive. All NHLs were vimentin positive, keratin negative. All NHLs except one expressed also LCA. It is concluded that keratin, vimentin and LCA are useful markers in differential diagnosis of malignant melanoma versus carcinoma and non-Hodgkin's lymphoma in fine needle aspirates when used together with morphologic and clinical data. However, in differential diagnosis of malignant melanoma and sarcoma these markers are of little use.

Entities:  

Mesh:

Year:  1991        PMID: 1845482

Source DB:  PubMed          Journal:  Patol Pol        ISSN: 0031-3114


  2 in total

1.  The cytological, immunocytochemical and molecular genetic analysis in diagnosis of the neoplasms of the eye, eye adnexa and orbit.

Authors:  Z Krzystolik; A Rosławska; E Bedner
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

Review 2.  Cytologic diagnosis of metastatic melanoma by FNA: A practical review.

Authors:  Andrea Ronchi; Marco Montella; Federica Zito Marino; Giuseppe Argenziano; Elvira Moscarella; Gabriella Brancaccio; Giuseppe Ferraro; Giovanni Francesco Nicoletti; Teresa Troiani; Renato Franco; Immacolata Cozzolino
Journal:  Cancer Cytopathol       Date:  2021-07-26       Impact factor: 4.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.